Gang Liu Wenxuan Zhou Xiaoli Li Lijie Guo Tingting He Juan Zhao Liansheng Gong
10.3389/fimmu.2021.712351
Front Immunol
2021 Aug 24;12:712351.
hcc pd-1 pd-l1 atezolizumab immunotherapy pembrolizumab
CC BY
https://pubmed.ncbi.nlm.nih.gov/34504494/
Antineoplastic Combined Chemotherapy Protocols / therapeutic use B7-H1 Antigen / antagonists & inhibitors Carcinoma, Hepatocellular / drug therapy Liver Neoplasms / drug therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors
Antineoplastic Combined Chemotherapy Protocols / therapeutic use B7-H1 Antigen / antagonists & inhibitors Carcinoma, Hepatocellular / drug therapy Liver Neoplasms / drug therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors Case Reports Research Support, Non-U.S. Gov't Angiogenesis Inhibitors / administration & dosage Antibodies, Monoclonal, Humanized / administration & dosage Bevacizumab / administration & dosage Carcinoma, Hepatocellular / diagnostic imaging Carcinoma, Hepatocellular / immunology Drug Substitution Female Hepatitis B, Chronic / complications Humans Immune Checkpoint Inhibitors / administration & dosage Liver Cirrhosis / etiology Liver Neoplasms / diagnostic imaging Liver Neoplasms / immunology Middle Aged Phenylurea Compounds / administration & dosage Portal Vein Quinolines / administration & dosage Salvage Therapy Tomography, X-Ray Computed Venous Thrombosis / etiology Angiogenesis Inhibitors Antibodies, Monoclonal, Humanized B7-H1 Antigen CD274 protein, human Immune Checkpoint Inhibitors PDCD1 protein, human Phenylurea Compounds Programmed Cell Death 1 Receptor Quinolines Bevacizumab atezolizumab pembrolizumab lenvatinib
PMC8422947
34504494
Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
2021